- Home
- MDXH vs NVCT Comparison
MDXH vs NVCT Comparison
Compare MDXH & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- NVCT
- Stock Information
- Founded
- MDXH 2003
- NVCT 2020
- Country
- MDXH Belgium
- NVCT United States
- Employees
- MDXH N/A
- NVCT N/A
- Industry
- MDXH
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- MDXH
- NVCT Health Care
- Exchange
- MDXH Nasdaq
- NVCT Nasdaq
- Market Cap
- MDXH 203.4M
- NVCT 167.0M
- IPO Year
- MDXH 2021
- NVCT 2022
- Fundamental
- Price
- MDXH $4.92
- NVCT $6.71
- Analyst Decision
- MDXH Buy
- NVCT Strong Buy
- Analyst Count
- MDXH 1
- NVCT 3
- Target Price
- MDXH $6.00
- NVCT $15.33
- AVG Volume (30 Days)
- MDXH 274.6K
- NVCT 114.1K
- Earning Date
- MDXH 11-12-2025
- NVCT 11-05-2025
- Dividend Yield
- MDXH N/A
- NVCT N/A
- EPS Growth
- MDXH N/A
- NVCT N/A
- EPS
- MDXH N/A
- NVCT N/A
- Revenue
- MDXH $98,953,000.00
- NVCT N/A
- Revenue This Year
- MDXH $24.43
- NVCT N/A
- Revenue Next Year
- MDXH $21.00
- NVCT N/A
- P/E Ratio
- MDXH N/A
- NVCT N/A
- Revenue Growth
- MDXH 22.56
- NVCT N/A
- 52 Week Low
- MDXH $1.35
- NVCT $4.44
- 52 Week High
- MDXH $5.33
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- MDXH 64.64
- NVCT 61.14
- Support Level
- MDXH $4.71
- NVCT $5.61
- Resistance Level
- MDXH $5.33
- NVCT $7.00
- Average True Range (ATR)
- MDXH 0.30
- NVCT 0.34
- MACD
- MDXH 0.05
- NVCT 0.09
- Stochastic Oscillator
- MDXH 72.11
- NVCT 79.14
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.